Prosecution Insights
Last updated: July 17, 2026
Application No. 18/555,301

METHOD FOR PREPARING LACTONES HAVING AT LEAST ONE GROUP SELECTED FROM CARBOXYL, CARBOALKOXY, HYDROXY AND CARBOXYLATE

Non-Final OA §103§112
Filed
Oct 13, 2023
Priority
May 04, 2021 — EU 21172097.4 +2 more
Examiner
CHANDRAKUMAR, NIZAL S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF SE
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
1284 granted / 1768 resolved
+12.6% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
89 currently pending
Career history
1858
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
33.5%
-6.5% vs TC avg
§102
6.6%
-33.4% vs TC avg
§112
37.9%
-2.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1768 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Prefatory Note: Multiple attempts using telephone to reach Attorney of Record for this case to explore compact prosecution failed. Election/Restrictions Applicant's election with traverse of Group I in the reply filed on 02/06/2026 is acknowledged. The traversal is on the ground(s) that A. PNG media_image1.png 48 622 media_image1.png Greyscale B. All the groups are PNG media_image2.png 14 162 media_image2.png Greyscale C. PNG media_image3.png 44 618 media_image3.png Greyscale None of the reasons is found persuasive because While PNG media_image4.png 52 594 media_image4.png Greyscale is given due consideration just as any other papers in the Application File wrapper is given due consideration, this Examiner is not bound by the conclusions of the PNG media_image5.png 46 596 media_image5.png Greyscale B. Applicant overlooks the following phrase in the previous action PNG media_image6.png 56 628 media_image6.png Greyscale with regards to the multiple groups (key word here is PNG media_image7.png 16 66 media_image7.png Greyscale and also Applicant overlooks the following phrase in the previous action at page 6, line 10 PNG media_image8.png 20 424 media_image8.png Greyscale and related arguments presented under this section (more on this below). C. Applicant overlooks the following phrase in the previous action PNG media_image9.png 60 610 media_image9.png Greyscale and arguments presented under this section. In addition to the above, Applicant is not responsive to the arguments, other than one pointed out above with respect to classification, for example multiple citations to support search, at page 7 of previous action. Therefore, the requirement is still deemed proper and is therefore made FINAL. Suggestion: See MPEP 818.01 Claims 11-16 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 02/06/2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10, 17-20 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 77-92-9 585-84-2 The structural identity of the starting material, product, solvent and other process parameters are vaguely defined. The language for the starting material PNG media_image10.png 74 560 media_image10.png Greyscale is confusing because it is unclear whether the three C atoms can be in the alcohol part of ester (to make up the 3Cs for the total mandatory 6Cs). Except for the indication that the total number of the C atoms as 6 and the mandatory requirement of three carboxylic acid groups present as starting materials, structural makeup of the compounds undergoing the reduction (hydrogenation) to make lactones (cyclic esters) is defined in convoluted manner. Further it is unclear, in a conceivable starting materials such as PNG media_image11.png 80 320 media_image11.png Greyscale (all 6C tricarboxylic acids) \how (in what conditions of process parameters) only one (or two or which ones) of the COOHs is/are preferentially reduced. The PNG media_image12.png 16 240 media_image12.png Greyscale language is confusing. The language ‘preparing’ with regards to starting materials demands (the need for) method for making the starting materials. No such method for making starting materials is present in the claims. In addition to starting materials and products, other process parameters are also recited in incomplete and vague language. Consider for example, the language for the solvent indicated as ‘providing or preparing’. Again while the term ‘providing’ is understood, the term ‘preparing’ requires the step or steps to make the solvent. The step or steps for this is/are not recited. The solvent is also indicated with a property without an upper limit. It is not a breadth issue, rather clarity issue. Similarly what reagent or reagent(s) promote(s) lactonization as opposed to esterification if an alcohol solvent is used. Further what limits intramolecular esterification (for lactone formation) vs esterification (with alcohol solvent) without further reduction is unclear. There is no reagent recited here for the (essential) step of lactonization (for the removal of elements of water from the intermediates, that is dehydration). It is noted that necessary reagent may be embedded in the ‘catalyst’ for performing hydrogenation and dehydration. However catalysis is generally considered unpredictable merely from the chemical nature of the catalyst. See Corona Co. v. Dover; (USSC 1928) 276 US 358, 369. Catalytic effects are not ordinarily predictable with certainty. In re Doumani et al. (CCPA 1960) 281 F2d 215, 126 USPQ 408. The effect of a modification of one prior art catalytic process in a manner employed in another prior art process which employs a different catalyst was held unpredictable in Ex parte Berger et al. (POBA 1952) 108 USPQ 236. There is no indication of stoichiometry in the reduction step. Assuming the indicated pressure implicitly recites this, there is no recitation as to why or how only one (or two) of the COOH groups is reduced. Claim language ‘when the starting compound is an aliphatic tricarboxylic acid’ has the connotation for the feasibility of aromatic starting material possibility. An aromatic system with three COOH groups defies commonly understood elementary principles of aromaticity. With the required BRI, limitations from the specification are not imported into claim interpretation. As stated in In re Zletz, 13 USPQ2d 1320, 1322, “An essential purpose of patent examination is to fashion claims that are precise, clear, correct and unambiguous.” Dependent claims do not solve the problems of the base claim. For example claim 17 the starting material consists of tricarboxylic acids. Because of the claim language PNG media_image13.png 44 580 media_image13.png Greyscale It is unclear with the ‘thereof’ term, esters of all three acid functions are in the starting materials and the 6C includes (C atoms that could be present in the alcohol part of the ester group). Consider claim 10, with the ‘open-ended’ comprising language with respect to the ‘product’. Here the ‘product’ (elaborately defined by the hydrogenation chemistry method in the base claim 1), now is not limited to lactones. The product here now includes the mandatory ‘lactones’ and has transitioned to a product comprising biological materials such as viruses and nucleic acids. The use of the term "comprising" in the instant Markush groupings causes the claims to be completely open-ended when a Markush grouping is "by its nature" a closed grouping of alternatives. Therefore, the use of “comprising” in the instant Markush-type claims renders the claims indefinite. As per “Ex parte Davis, 80 USPQ 448, 450 (Bd. App. 1948) ("comprising" leaves "the claim open for the inclusion of unspecified ingredients even in major amounts"). In Gillette Co. v. Energizer Holdings Inc., 405 F.3d 1367, 1371-73, 74 USPQ2d 1586, 1589-91 (Fed. Cir. 2005), the court held that a claim to "a safety razor blade unit comprising a guard, a cap, and a group of first, second, and third blades" encompasses razors with more than three blades because the transitional phrase "comprising" in the preamble and the phrase "group of" are presumptively open-ended. "The word ‘comprising’ transitioning from the preamble to the body signals that the entire claim is presumptively open-ended." Id. In contrast, the court noted the phrase "group consisting of" is a closed term, which is often used in claim drafting to signal a "Markush group" that is by its nature closed. Id. The court also emphasized that reference to "first," "second," and "third" blades in the claim was not used to show a serial or numerical limitation but instead was used to distinguish or identify the various members of the group. Id.” The examiner points out the use of the term "comprising" in the instant Markush groupings causes the claims to be completely open-ended when, as stated above, a Markush grouping is "by its nature" a closed grouping of alternatives. Therefore, the use of “comprising” in the instant Markush-type claims renders the claims indefinite. A comprehensive patent search could not be done. As such dependent claims do not resolve the issues of base claim 1. As such claims 2-10, 17-20 are rejected as well. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1 and 2 are rejected under 35 U.S.C. 103 as being unpatentable over Verduyckt, Green Chem.,2017,19, 4642–4650; JP2018168135 and JP2018168136 Verduyckt at page 4644, Scheme 1 teaches hydrogenation of PNG media_image14.png 50 556 media_image14.png Greyscale starting materials PNG media_image15.png 84 90 media_image15.png Greyscale to make lactone PNG media_image16.png 60 94 media_image16.png Greyscale The starting materials noted above is the same as in the exemplifications disclosed at page 10, line 22-24 of instant specification. The Verduyckt PNG media_image17.png 16 50 media_image17.png Greyscale product falls under the scope of the instantly lactone product as defined: PNG media_image17.png 16 50 media_image17.png Greyscale consisting of PNG media_image18.png 16 58 media_image18.png Greyscale group. The catalyst Ni used in the above pointed out Verduyckt chemistry and taught by Verduyckt in the opening statement of the reference as an alternative to Pd catalyst (as per claim 2) is same as limited in claim 1 (Ni and Pd) and 2 (Pd). Though Verduyckt teaches the limitations of base claim 1, the starting materials including hydrogen, reagent (catalyst), solvent and product, Verduyckt hydrogenation does not teach all the (vaguely) recited starting materials and products or process parameters/conditions as instantly recited: PNG media_image19.png 72 468 media_image19.png Greyscale As per Examination guidelines, it has been held that where the general conditions (in the instant case temperature and pressure) of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. The differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Furthermore, hydrogenation of 6C tricarboxylic starting materials to make lactone products is taught in JP2018168136 at numbered page 2 and at pages 9-10 products in generic chemical formulae. These generic formulae encompass the instantly recited starting materials and products. For 6C tricarboxylic starting material citric acid see page 2, line 31. Similarly, JP2018168135 teaches the same hydrogenation reaction including the specific starting material aconitic acid at page 2 and for isomers of 5-membered lactone products see bottom of page 9 on to page 10. There is no comparative data for (the difference pointed out above) for secondary consideration. As such nothing unobvious is seen in the claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NIZAL S CHANDRAKUMAR/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Oct 13, 2023
Application Filed
Oct 13, 2023
Response after Non-Final Action
May 12, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678466
Method to Improve Therapeutic Properties of Stem Cells
3y 0m to grant Granted Jul 14, 2026
Patent 12673928
PROCESS FOR THE PRODUCTION AND SEPARATION OF 5-HYDROXYMETHYLFURFURAL WITH QUATERNARY AMMONIUM SALTS
5y 5m to grant Granted Jul 07, 2026
Patent 12667619
INTEGRIN TARGETING LIGANDS AND USES THEREOF
5y 8m to grant Granted Jun 30, 2026
Patent 12661316
CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS
3y 3m to grant Granted Jun 23, 2026
Patent 12653818
PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXOLINE LYSINATE, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 5m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
91%
With Interview (+18.3%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1768 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month